A major milestone occurred in the late 1960s when physicians began to treat occult central nervous system leukemia. Realizing that central nervous system was present but not measurable, clinicians at St. Jude Children's Research Hospital began to use cranial radiation and later intrathecal therapy prophylactically to prevent the spread of hidden disease. The 1970s witnessed the dramatic results of this therapy, as the first "cures" were recognized and survival rates improved dramatically to over 50%. The 1980s witnessed the development of risk-based therapy and the beginnings of bone marrow transplantation as therapy for children with refractory or relapsed leukemia. The 1990s saw the application of the knowledge and tools of molecular biology, and a uniform system of risk classification was developed. European investigators from Berlin, Frankfurt, and Munich (BFM) intensified postinduction therapy (consolidation) by using higher doses and cycling multiple agents (the BFM regimen). This type of approach has resulted in a significant improvement in survival, especially for patients at high risk of failure.
The first decade of the twenty-first century saw the merger of the CCG and Pediatric Oncology Group into the Children's Oncology Group, the incorporation of the molecularly targeted tyrosine kinase inhibitor, imatinib mesylate, in treatment for patients with Philadelphia chromosome-positive ALL, use of a long-acting form of PEG L-asparaginase in newly diagnosed patients, and approval of nelarabine for patients with recurring T-cell ALL and clofarabine for patients with recurring ALL. Retrospective studies have shown that young adults with ALL treated with pediatric protocols have a better outcome. Optimal treatment for older patients still remains a challenge. Selecting therapy based on patient-and disease-specific prognostic factors has led to a significant improvement in outcomes for childhood ALL, and the more recent adoption of this approach for adults has had a similar favorable impact.
